Hidradenitis suppurativa (HS) Program in Pharmaceutical Benefits Scheme (PBS) 012-18051119

HS restriction and item codes

Do not release this attachment externally. See Freedom of Information - Information Publication Scheme.

$\\INTERNAL.DEPT.LOCAL\Shared\NAT\SERDELEXCEL\WORKPRODIMP\Operation Blueprint Migration\RDT Release Icons\32w\icon-hidden-attachment.png$ PBS HS restriction and item codes

Contact details

PBS Complex Drugs Programs

Forms

Moderate to severe hidradenitis suppurativa - initial, change or recommencement authority application (PB218)

Moderate to severe hidradenitis suppurativa - secukinumab - initial grandfather authority application (PB364)

Moderate to severe hidradenitis suppurativa - continuing authority application (PB219)

Services Australia website

Hidradenitis Suppurativa

External websites

PBS schedule for Hidradenitis suppurativa

FAQs from Service Officers

Table 1: see Table 2 in Processing Complex Authority Required Listings for FAQs about all Complex programs.

Item	Description
1	How many failures are allowed in one treatment cycle for PBS-subsidised treatment of hidradenitis suppurativa (HS)? Three. As there are only two biological medicines PBS listed to treat HS, patients can fail one biological medicine twice within the same treatment cycle.
2	How many prescriptions are required for an authority application for the initial, change or recommencement of treatment with adalimumab? Two. One should be for the loading, written for a quantity of 6 (of 40 mg) or 3 (of 80 mg) and no repeats, with 160 mg administered at week 0, 80 mg at week 2 and 40 mg weekly starting at week 4. This prescription must be included with the HS initial/change/recommencement application form (PB218) The second one should be for the balance of 16 weeks of treatment with a quantity of 4 (of 40 mg) or 2 (of 80 mg) and 2 repeats. This request can be made in real time using the Online PBS Authorities (OPA) system or by phone.
3	How many prescriptions are required for an authority application for the initial, change or recommencement of treatment with secukinumab? Prescribers must submit either: 2 prescriptions if an induction regimen is intended. One should be for the induction, containing a quantity of 8 doses of 150 mg and no repeats. This prescription must be included with the application form (PB218). The second one should be for the maintenance with 2 (or 4) doses of 150 mg and 3 repeats. If not provided, the approval of the second (balance) prescription can be made in real time using the OPA system or by phone. 1 prescription if no loading dose is requested. This prescription should be for a quantity of 2 (or 4) doses of 150 mg and 3 repeats and must be included with the application form (PB218). Note: see HS code sheet for the correct item code(s), quantity and repeats to be entered in the OPA system.
4	Can increased quantity and/or repeats be authorised for secukinumab? The quantity of secukinumab can be increased from 2 to 4 for all treatment phases (excluding the induction) if the patient is dosed at 300 mg per fortnight. No increase in the maximum number of listed repeats can be authorised. Note: see HS code sheet for details.